Stockscreener 앱 받기
4.7004
15.41%
-0.8796
전일 마감가:
$5.58
열려 있는:
$5.47
하루 거래량:
88,147
Relative Volume:
0.03
시가총액:
$5.53M
수익:
$212.10K
순이익/손실:
$-40.19M
주가수익비율:
-0.000885
EPS:
-5313.2836
순현금흐름:
$-13.92M
1주 성능:
-5.60%
1개월 성능:
-62.09%
6개월 성능:
-98.82%
1년 성능:
-99.99%
1일 변동 폭
$4.61
$5.49
1주일 범위
$4.17
$5.7685
52주 변동 폭
$4.11
$34,200.00
애디텍스트 Stock (ADTX) Company Profile
명칭
Aditxt Inc
전화
909-488-0844
주소
737 N. FIFTH STREET, SUITE 200, RICHMOND
ADTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ADTX
Aditxt Inc
|
4.7004 | 5.53M | 212.10K | -40.19M | -13.92M | -5,313.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.68 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
587.39 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
559.38 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
244.97 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
240.59 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
애디텍스트 주식(ADTX)의 최신 뉴스
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Appili President And CEO, Don Cilla To Join Aditxt CEO, Amro Albanna For Aditxt Weekly Update On April 4, 2025 - MarketScreener
Appili Therapeutics CEO to Discuss Strategic Growth and Funding Initiatives - TipRanks
Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025 - The Manila Times
Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025 - Bluefield Daily Telegraph
$117M Federal Funding Applications: Aditxt and Appili CEOs to Unveil Major Biodefense Strategy - Stock Titan
Aditxt, Inc. SEC 10-K Report - TradingView
Aditxt, Inc. Updates on Pearsanta’s Strategic Acquisition - TipRanks
BioMedNewsBreaks — Evofem Biosciences Inc. (EVFM) Releases Second-Quarter 2024 Financial Results, Company Update - MSN
Upcoming Aditxt Weekly Update to Highlight Pearsanta's Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection - Quantisnow
Upcoming Aditxt Weekly Update to Highlight Pearsanta’s Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection - Business Wire
Aditxt, Inc. extends merger agreement with Evofem Biosciences By Investing.com - Investing.com Australia
Aditxt, Inc. extends merger agreement with Evofem Biosciences - Investing.com India
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Evofem Reports Fourth Consecutive Year of Net Sales Growth - Quantisnow
Aditxt, Inc. Highlights Strategic Partnership with Evofem - TipRanks
Evofem Posts Record 4th Year Growth: Revenue Up 6% as Operating Costs Plunge 27% - Stock Titan
Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk - Business Wire
SEC Form 10-K filed by Evofem Biosciences Inc. - Quantisnow
Evofem Biosciences Inc. (EVFM) reports earnings - Quartz
Small Cap Stocks To Follow TodayMarch 19th - MarketBeat
Top Small Cap Stocks To ResearchMarch 18th - MarketBeat
Aditxt Provides Business Status Overview and Announces Launch of Aditxt Weekly Update Starting Friday, March 21, 2025 - Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025 - Marketscreener.com
Aditxt Shares Up After Acquisition Target Appili Files Funding Plans - MarketScreener
Top Midday Gainers -March 18, 2025 at 02:10 pm EDT - MarketScreener
S&P 500 Down 1%; Sarepta Therapeutics Shares Plunge - Benzinga
Why Aditxt (ADTX) Stock Is Skyrocketing - Benzinga
Aditxt more than doubles after Appili takeover deadline extended - TradingView
Dow Dips Over 200 Points; US Industrial Production Increases More than Expected - Benzinga
Appili Therapeutics expects Aditxt transaction to close in Q1 - TipRanks
Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update - Lelezard
Appili Therapeutics Announces Submission Of US Federal Government Funding Proposals And Provides Corporate And Aditxt Transaction Update - Marketscreener.com
Aditxt advances on drug trials and acquisition strategies By Investing.com - Investing.com Australia
Dow Jumps 400 Points; US Retail Sales Increase Less Than Expected - Benzinga
Aditxt advances on drug trials and acquisition strategies - Investing.com India
Aditxt Reveals Ambitious Roadmap: Multiple Clinical Trials and 2025 Product Launch - StockTitan
Upcoming Stock Splits This Week (March 17 to March 21) – Stay Invested - The Globe and Mail
Aditxt announces 1-for-250 reverse stock split effective March 17 - MSN
Aditxt shares fall on 1-for-250 reverse stock split - MSN
ADTX stock plunges to 52-week low, touches $0.04 - Investing.com India
Crude Oil Falls 1%; Dollar General Posts Upbeat Sales - Benzinga
Nasdaq Down Over 100 Points; US Producer Inflation Stalls In February - Benzinga
ADTX stock plunges to 52-week low, touches $0.04 By Investing.com - Investing.com Australia
US Stocks Likely To Open Lower After A Brief Respite: 'Add Exposure To Equities' Amid Pullback, Says Expert - Benzinga
Why Intel Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - Benzinga
Aditxt announces 1-for-250 reverse stock split By Investing.com - Investing.com Australia
Aditxt announces 1-for-250 reverse stock split - Investing.com
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Aditxt, Inc. Announces Reverse Stock Split Plan - TipRanks
애디텍스트 (ADTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
애디텍스트 주식 (ADTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| HRT FINANCIAL LP | 10% Owner |
Oct 16 '24 |
Sale |
1.17 |
25,534 |
29,875 |
0 |
2.65%
0.06%
자본화:
|
볼륨(24시간):